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Abstract 
RRx-001, an experimental systemically non-toxic epi-immunotherapeutic agent, which poten-
tiates the resensitization of resistant cancer cells to formerly effective therapies, is under ac-
tive investigation in several clinical trials that are based on sequential or concomitant rechal-
lenge to resistant first- or second-line regimens. One of these trials is designated TRIPLE 
THREAT (NCT02489903), because it explores the conditioning or priming effect of RRx-001 
on three tumor types – non-small cell lung cancer (NSCLC), small cell lung cancer and high-
grade neuroendocrine tumors – prior to re-administration of platinum doublets. In follow-up 
to a recent case study, which describes early monotherapeutic benefit with RRx-001 in a re-
fractory EGFR-mutated NSCLC tumor, we present subsequent evidence of a radiological par-
tial response to reintroduced platinum doublets after RRx-001. For the 50% of patients with 
EGFR-mutated NSCLC who progress on EGFR-tyrosine kinase inhibitors (without evidence of 
a T790M mutations) as well as platinum doublets and pemetrexed/taxane, no other clinically 
established treatment options exist. A retrial of these therapies in EGFR-positive NSCLC pa-
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tients via priming with epigenetic agents such as RRx-001 constitutes a strategy to ‘episensi-
tize’ tumors (i.e. reverse resistance by epigenetic means) and to extend overall survival. 
 © 2016 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
Therapy selection guidelines for EGFR-mutated non-small cell lung cancer (NSCLC) pa-
tients are as follows: 
 First line: tyrosine kinase inhibitors (TKIs) for EGFR-sensitizing mutations (exons 
18,19, and 21), including erlotinib [1] and afatinib [2], approved for use in the Unit-
ed States, as well as gefitinib [3], which has recently received reapproval for use in 
the United States. 
 Second-line TKIs: upon progression, it is recommended to biopsy the site of pro-
gression to determine if a new resistant mutation has developed (exon 20 muta-
tion) T790M. If this new resistant mutation exists, patients are now offered osimer-
tinib [4], which has recently been approved in the United States. 
 Second line if the patient has no T790M mutation: 4–6 cycles of platinum-based 
chemotherapy such as platinum/pemetrexed [5], after which patients are observed 
for evidence of disease progression [6]. Third-line therapy generally follows pro-
gression. Elderly patients with significant comorbidities appear to tolerate the plat-
inum doublets, carboplatin and nanoparticle albumin-bound paclitaxel with a re-
duced toxicity profile as an option [7]. 
 Third line: single agent docetaxel or pemetrexed (whichever has not been used so 
far). After disease progression, in the absence of clinical deterioration, patients may 
be referred for clinical trials (fig. 1). 
While the successful reintroduction to TKIs or standard chemotherapy after progression 
in EGFR-mutated NSCLC patients has been documented in the literature [8], a rechallenge 
strategy is generally contraindicated on the assumption that re-exposure will yield toxicity 
rather than benefit due to the stability of the chemo-resistant phenotype [9, 10]. An emerg-
ing paradigm called episensitization, which attempts to epigenetically condition or ‘prime’ 
the tumor to re-respond to refractory chemotherapy, challenges the long-held practice of 
permanently discontinuing a particular treatment at the time of disease progression [11]. 
Hypothetically, like a therapeutic ‘do-over’, episensitized patients restart prior effective reg-
imens each time from a state of scratch rather than from the disadvantage of a progressively 
entrenched non-responsiveness, potentially leading to the ‘chronification’ of a once fatal 
disease. Accordingly, in a phase II clinical trial called TRIPLE THREAT (NCT02489903), pa-
tients with three tumor types – NSCLC, small cell lung cancer and high-grade neuroendo-
crine tumors or carcinomas (hence the name TRIPLE THREAT) – receive the experimental 
systemically non-toxic immuno-epigenetic agent, RRx-001 [12–14], until RECIST v. 1.1-
defined progression, followed by the reintroduction of platinum doublets. Figure 2 shows a 
schematic description of the TRIPLE THREAT trial. 
In the present report, a follow-up to a recently published case report in this journal [15], 
which details dramatic RRx-001-induced intratumoral necrosis and immune infiltration in 
an EGFR-mutated NSCLC patient, evidence of subsequent episensitization to platinum dou-
blets in the form of a partial response is described. 
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Case  
A 49-year-old never-smoking male with EGFR-sensitizing positive mutated NSCLC and 
clear failure to erlotinib as well as carboplatin and pemetrexed received 5 weekly doses of 
intravenous RRx-001 (4 mg) with simultaneous infusions of autologous blood per the TRI-
PLE THREAT (NCT02489903) protocol. In the 5th week of treatment, he was reimaged with 
PET/CT due to progressively worsening abdominal pain, which demonstrated a dramatically 
enlarged necrotic mass with a thin capsule of apparently viable tumor (fig. 3). 
Despite this clearly beneficial response to treatment, tumor enlargement mandated dis-
continuation of RRx-001 per RECIST v.1.1 criteria for progression, and the patient was re-
started on platinum doublets (cisplatin 75 mg/m2 i.v. + nab-paclitaxel 100 mg/m2 i.v.). After 
only one cycle, the patient, coping poorly with the persistent abdominal pain, nausea, ca-
chexia, and fatigue, due to the size of the mass, requested an extended break from treatment 
to spend time with his wife and small children. Almost 3 weeks later, the investigators were 
pleasantly surprised when the patient called to report that his energy, appetite, productivity, 
and weight had recovered in the absence of treatment to the point that for the first time in 
recent memory he was looking forward to the holidays. 
On December 22, 2015, the patient was reimaged with PET/CT, which demonstrated a 
partial response (30% decrease in sum from baseline) as well as a metabolic response rela-
tive to the previous PET/CT on November 27, 2015. These images are shown (fig. 3). 
Discussion 
This follow-up case report documents an unprecedented clinical and radiological partial 
response of a patient with platinum and TKI-refractory EGFR-mutated NSCLC with no fur-
ther treatment options, having progressed through multiple lines of targeted and systemic 
chemotherapy, including a previous clinical trial with TH-4000 (tarloxotinib), a pro-drug of a 
TKI [16], which did not benefit the patient. His response was all the more remarkable be-
cause it occurred after only one dose of protocol-mandated rechallenge with platinum dou-
blets, demonstrating a potential epigenetic resensitization i.e. ‘episensitization’ due to RRx-
001 pretreatment or priming. 
Patients with platinum and TKI-refractory EGFR-mutated NSCLC have an average sur-
vival measured in months only [17]. Moreover, from the moment that treatment starts in 
first line, the clock is winding down along with viable therapeutic options, and it is only a 
question of time when – rather than if – resistance and treatment failure will occur. Since the 
accumulation of treatment-induced epigenetic changes are in theory reversible [18], unlike 
genetic mutations, the episensitization tabula rasa has the potential to wipe the resistance 
slate clean and rewind the ticking doomsday clock all the way back to first or second line. 
The result, hopefully, is improved functional status and overall survival, translating to more 
quality time, which is what occurred in the case of this fortunate patient. 
Statement of Ethics 
The case report was conducted according to the Declaration of Helsinki principles. The 
patient gave written informed consent. 
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Fig. 1. NSCLC EGFR mutation-positive treatment algorithm. 
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Fig. 2. Schema of the TRIPLE THREAT clinical trial. SCLC = Small cell lung cancer; HGNEC = high-grade 
neuroendocrine carcinoma; PD = progressive disease; SD = stable disease. 
 
 
 
Fig. 3. On the left, PET/CT from November 27, 2015 demonstrating RRx-001-induced central infarction of 
an abdominal metastasis. On the right, PET/CT from December 22, 2015 showing dramatic shrinkage of 
the lesion after one dose of cisplatin and pemetrexed, indicative of episensitization. The high FDG uptake 
in the discontinuous rind of the tumor may be secondary to invasion by inflammatory cells. Note the FDG-
avid myocardium just above the tumor on the left. 
 
